Bull Market-Year Two | Daily Market Update

Posted by

Monday, March 22, 2021

Top Story

The Second Year Of The Bull Market Begins

LPL Research discuss the end of the bear market and the trends of a bull market in year two in this week’s Weekly Market Commentary, available at 1 p.m. ET.

Daily Insights

U.S. stocks open higher to begin the week with Nasdaq leading as yields dip

  • European markets are mixed in midday trading.
  • Asian stocks finished mixed overnight, with Japan under pressure amid concerns over chip shortage.
  • Plunge in the Turkish Lira dominated headlines over the weekend after its president removed the country’s central bank chief.

Week ahead

The following economic data is slated to be released this week:

  • Monday: National Association of Realtors (NAR) existing home sales (Feb.)
  • Tuesday: U.S. Census February building permits, new home sales, and Q4 current accounts
  • Wednesday: Durable orders (Feb.), Markit PMI Manufacturing and Services reports (Feb.)
  • Thursday: Weekly initial and continuing claims, revised Q4 GDP
  • Friday: Personal consumption expenditure and Income report and wholesale inventories (Feb.)

Technical update

The S&P 500 Index ended last week with a slight loss, but still managed several record high closes early in the week. Markets are little changed in early trading, but the Nasdaq is leading to the upside. 13,607 is the key resistance level to watch for the Nasdaq Composite.

COVID-19 news

The United States reported 33,000 new COVID-19 cases on Sunday, down 13% week over week (source: Johns Hopkins).

  • New case growth remains more concentrated in northern states with cooler weather, with Michigan in particular seeing cases triple over the past month.
  • Hospitalizations and deaths in the U.S. continue to decline thanks to vaccination efforts, as more than 20% of the population has received at least one dose of the vaccine.
  • Cases in Western Europe (ex-United Kingdom) continue to climb, prompting several countries in the region to extend or increase restrictions on activity.
  • U.S. clinical trial finds the vaccine developed by AstraZeneca to be 79% effective in preventing COVID-19. The vaccine has come under scrutiny by many European countries and the results were better than expected.

 

IMPORTANT DISCLOSURES

This material is for general information only and is not intended to provide specific advice or recommendations for any individual. There is no assurance that the views or strategies discussed are suitable for all investors or will yield positive outcomes. Investing involves risks including possible loss of principal. Any economic forecasts set forth may not develop as predicted and are subject to change.

References to markets, asset classes, and sectors are generally regarding the corresponding market index. Indexes are unmanaged statistical composites and cannot be invested into directly. Index performance is not indicative of the performance of any investment and do not reflect fees, expenses, or sales charges. All performance referenced is historical and is no guarantee of future results.

Any company names noted herein are for educational purposes only and not an indication of trading intent or a solicitation of their products or services. LPL Financial doesn’t provide research on individual equities.

All information is believed to be from reliable sources; however, LPL Financial makes no representation as to its completeness or accuracy.

All index and market data are from FactSet and MarketWatch.

This Research material was prepared by LPL Financial, LLC.

Securities and advisory services offered through LPL Financial (LPL), a registered investment advisor and broker-dealer (member FINRA/SIPC).

Insurance products are offered through LPL or its licensed affiliates.  To the extent you are receiving investment advice from a separately registered independent investment advisor that is not an LPL affiliate, please note LPL makes no representation with respect to such entity.

  • Not Insured by FDIC/NCUA or Any Other Government Agency
  • Not Bank/Credit Union Guaranteed
  • Not Bank/Credit Union Deposits or Obligations
  • May Lose Value

For Public Use – Tracking # 1-05124463